Enlightenment Pharmaceutical (000590.SZ) released its 2023 annual report. The company's revenue was 405 million yuan...
According to the Zhitong Finance App, Enlightenment Pharmaceutical (000590.SZ) released its 2023 annual report. The company's revenue was 405 million yuan, an increase of 15.44% over the previous year. Net profit attributable to shareholders of listed companies was RMB 25.2468 million, an increase of 39.41% over the previous year. The net loss attributable to shareholders of the listed company after deducting non-recurring profit and loss was $4.655 million. Basic earnings per share were $0.1054.
According to the announcement, the increase in net profit attributable to shareholders of listed companies over the same period of the previous year was mainly due to non-recurring profit and loss, which mainly included: the company confirmed compensation income for land occupied by the government due to public infrastructure construction, the original shareholders of the subsidiary Guangdong Xiantong Pharmaceutical Co., Ltd. needed to pay compensation to the company for not fulfilling performance promises, and confirmation of an increase in non-recurring profit and loss due to government subsidy revenue.